ZLMT-72

• Description :

  ZLMT-72 is an orally active dual CDK2 and CDK9 inhibitor with IC50s of 0.741 nM and 1.03 nM, respectively. ZLMT-72 shows good selectivity in kinase profiling andcholinesterase inhibition activity. ZLMT-72 has strong antiproliferative effects in the colorectal cancer (CRC) cell line HCT116 (GI50 apoptosis by inhibiting thephosphorylation of retinoblastoma and RNA polymerase II, resulting in downregulation of antiapoptotic proteins (Mcl-1 and XIAP) . ZLMT-72 can be used for the study of colorectal cancer (CRC) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Bcl-2 Family; CDK; DNA/RNA Synthesis; IAP

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  O=C([C@@H]1[C@@H](F)C1)NC2=CC(C3=CC=C(N=C(CCCCC4)C4=C5N6C[C@@H](CNC7)[C@@H]7C6)C5=C3)=CC=N2

• Molecular Formula :

  C29H32FN5O

• Molecular Weight :

  485.60

• References & Citations :

  [1]Wu L, et al. Fluorocyclopropyl-Containing Tacrine Derivatives as Potent and Selective Dual CDK2/CDK9 Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2025;68 (22) :24326-24357.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK2; CDK9; Mcl-1; XIAP